University of Michigan
Ann Arbor, Michigan, United States
Dinesh Khanna, MD, MSc, is the Frederick G.L. Huetwell Professor of Medicine and Director, University of Michigan Scleroderma Program. Dr Khanna has published over 575 peer-reviewed articles and book chapters. Dr Khanna is the Coordinating PI for ongoing and recently completed NIH and industry-funded trials in scleroderma. His current research is focused on validating outcome measures, trial design, and understanding the mechanism of action(s) of novel targets in the context of scleroderma clinical trials. He led the development of American College of Rheumatology Combined Response Index in Systemic Sclerosis (ACR CRISS) and Revised CRISS. Dr Khanna is recipient of the Henry Kunkel Young Investigator Award from the American College of Rheumatology and member of the American Society for Clinical Investigation. He has been included in the Stanford’s Top 2% Scientists list from 2021-2024.
Sunday, October 26, 2025
3:00 PM - 3:15 PM Central Time
Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing); AstraZeneca: Consultant (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Cabaletta: Consultant (Ongoing); NKarta: Advisor or Review Panel Member (Ongoing); Novartis: Consultant (Ongoing); UCB: Consultant (Terminated, July 30, 2025)
Monday, October 27, 2025
10:30 AM - 12:30 PM Central Time
Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing); AstraZeneca: Consultant (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Cabaletta: Consultant (Ongoing); NKarta: Advisor or Review Panel Member (Ongoing); Novartis: Consultant (Ongoing); UCB: Consultant (Terminated, July 30, 2025)
ITS1: CAR T Cell Therapy in Autoimmune Disease: A Potential Emerging Treatment Option
Tuesday, October 28, 2025
5:30 PM - 7:30 PM Central Time
Disclosure information not submitted.